Long-acting transdermal patch of levothyroxine sodium
By using acrylic pressure-sensitive glue and permeability enhancer in levothyroxine sodium transdermal patch, the penetration and release performance of the drug is optimized, and the problem of strict requirements on the frequency and time of administration in levothyroxine sodium treatment is solved, and the problem of strict drug delivery frequency and time requirements is achieved. The continuous release and efficient absorption of drugs have improved patients' medication compliance.
Patent Information
- Application Number
- CN202411125730.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-05-09
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-16
AI Technical Summary
The existing treatment methods for levothyroxine sodium have strict requirements on the frequency and time of administration, gastrointestinal environmental interference, and unstable drug absorption, resulting in poor drug compliance and lack of an effective percutaneous drug delivery system.
A long-acting transdermal patch of levothyroxine sodium is used, including a backing layer, a medicinal pressure-sensitive adhesive layer and an anti-adhesion layer. Acrylic pressure-sensitive adhesive is used as the matrix, and isopropyl myristate, azalkone, Oleic acid and other permeability enhancers optimize the penetration and release performance of patches, improve the percutaneous penetration and release rate of the drug through in vitro experiments, and achieve the continuous release of levothyroxine sodium.
It has achieved good solubility, stability and continuous release of levothyroxine sodium, significantly improved the percutaneous penetration rate of the drug, extended the maintenance time of effective blood drug concentration, reduced the number of doses, and improved the patient's medication compliance. Avoid the impact of food and gastrointestinal environment on drug absorption.
Smart Images

Figure CN118986941A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of medicine, and relates to a transdermal drug delivery system of levothyroxine sodium, which is an artificially synthesized sodium salt of tetraiodothyronine, in particular to a levothyroxine sodium transdermal patch, which can be used for the treatment of hypothyroidism. Background Art
[0002] Hypothyroidism is a thyroid hormone deficiency caused by too little thyroid hormone secreted by thyroid follicular cells. Currently, the preferred treatment for hypothyroidism is oral levothyroxine sodium monotherapy, but gastric pH, gastrointestinal diseases, or dietary soy have been reported to interfere with the absorption of levothyroxine sodium. The requirements for the frequency and time of L-T4 administration are more rigid and strict. Patients need to strictly control the frequency and time of L-T4 administration, and patients have poor medication compliance. These factors lead to certain limitations in the oral route of levothyroxine. In this case, patients urgently need a convenient and durable alternative preparation.
[0003] The transdermal drug delivery system (TDDS) is a drug delivery system that uses the skin as a drug delivery channel. It is the third generation of drug preparations after oral preparations and injections. This route of administration is convenient, easy to use, and non-invasive. It uses long-acting preparations to reduce the number of dosings and can improve patient compliance. It can also reduce fluctuations in drug concentrations in the blood, provide stable plasma levels, and reduce the possibility of overdose. At the same time, it avoids the interference of the gastrointestinal environment, such as pH, enzyme activity, drug-food interactions, and the "first-pass effect" of the liver on drug efficacy. This dosage form can accurately solve the medication defects of oral levothyroxine sodium preparations and is a promising levothyroxine sodium preparation.
[0004] In the preparation of patches, the type of matrix patch is crucial. Polyacrylate pressure-sensitive adhesive is one of the most important and widely used types of pressure-sensitive adhesive. It is widely used in the preparation of patches due to its excellent adhesion, mechanical and chemical stability, good drug miscibility, and non-toxic, harmless, and low cost. The simplest form of pressure-sensitive adhesive patch is the drug-containing pressure-sensitive adhesive type, in which the drug is directly dissolved or dispersed into the pressure-sensitive adhesive polymer. The drug-containing pressure-sensitive adhesive matrix provides multiple functions, including skin adhesion, drug storage, and control of the penetration rate of drug penetration enhancers, and it also controls the distribution of active ingredients in the stratum corneum. It is a matrix type that is easy to prepare and has excellent effects.
[0005] Levothyroxine sodium is limited by its large relative molecular weight and is difficult to penetrate through intact skin without any enhancement. Chemical penetration enhancer method is an effective method to enhance drug skin penetration, which uses relatively inert chemicals to assist drug percutaneous absorption. The mechanism of action of chemical penetration enhancers usually acts on the stratum corneum, thereby reducing the resistance provided by intracellular keratin and intercellular lipid regions. Indirect effects include optimizing the thermodynamic activity of the drug, affecting the drug's partition coefficient, increasing the solubility of the drug in the carrier, and forming a drug reservoir in the skin.
[0006] In the treatment of hypothyroidism that requires long-term administration, a transdermal preparation that can continuously deliver drugs to the human body and reduce the frequency of administration is very useful. Therefore, the present invention discloses a transdermal preparation of levothyroxine sodium with good penetration effect, which can achieve long-term continuous release of levothyroxine sodium in the skin, overcome the problem of variable bioavailability caused by oral administration, and better meet the needs of clinical treatment.
[0007] At present, there are no relevant patents for transdermal administration of levothyroxine sodium at home and abroad, and almost all of them are oral preparations. In a foreign article, Stewart SA et al. (doi:10.1016 / j.ijpharm.2021.121011.) prepared a polycaprolactone-based subcutaneous implant for continuous delivery of levothyroxine. The skin implant is implanted subcutaneously, and the treatment duration can be up to four weeks. Ghazi RF et al. (doi:10.5599 / admet.1317.) prepared dissolving microneedles loaded with levothyroxine sodium for transdermal administration. An efficient transdermal drug delivery system for L-T4 was established by applying hyaluronic acid to dissolve microneedles. Based on microneedles, a sharp needle is used to pierce the top layer of the skin in a minimally invasive manner to create a physical channel. However, both microneedles and subcutaneous implants promote penetration through physical methods, which will cause certain damage to the skin and greatly reduce medication compliance. Summary of the invention
[0008] The purpose of the present invention is to provide a transdermal drug delivery system of levothyroxine sodium, which is a synthetic sodium salt of tetraiodothyronine, specifically a levothyroxine sodium transdermal patch.
[0009] The technical solution adopted by the present invention is: a long-acting transdermal patch of levothyroxine sodium, which comprises layers arranged in the following order: a backing layer, a drug-containing pressure-sensitive adhesive layer, and an anti-adhesive layer;
[0010] Features:
[0011] The backing layer and the anti-adhesive layer are both PET films;
[0012] The pressure-sensitive adhesive in the drug-containing pressure-sensitive adhesive layer is an acrylic pressure-sensitive adhesive; wherein the acrylic pressure-sensitive adhesive is 73%-97% by weight; the levothyroxine sodium is 3%-12% by weight; and the penetration enhancer is 0%-15% by weight;
[0013] The acrylic pressure-sensitive adhesive is selected from one of DURO-TAK 87-2287, DURO-TAK 87-2510, DURO-TAK 87-2852, DURO-TAK 87-4098, DURO-TAK 87-2051, and DURO-TAK 87-2052;
[0014] The drug-containing pressure-sensitive adhesive layer is added with 1-15% by weight of a penetration enhancer, which is selected from one of isopropyl myristate, azone, oleic acid, propylene glycol, polyglycerol fatty acid esters (IPM, NZ, OA, PG, POCC) or a combination thereof.
[0015] The in vitro permeation and release behaviors of the levothyroxine sodium patch are not ideal, so the present invention improves the in vitro permeation effect of the levothyroxine sodium patch from the two perspectives of permeation and release.
[0016] The levothyroxine sodium patch prepared by the present invention has good stability in the pressure-sensitive adhesive matrix, and the drug loading is as high as 9%, and no crystallization is observed in a one-month accelerated test, thereby achieving good solubility, release and stability of levothyroxine sodium.
[0017] The patch of the present invention has a thickness of 100 to 200 microns, and can maintain good air permeability and moisture permeability after being applied to the skin, thereby effectively reducing side effects such as skin irritation.
[0018] The present invention optimizes the prescription of the patch by an in vitro permeation experiment to improve the transdermal penetration rate of the drug. Determination method: A horizontal diffusion cell is used for an in vitro permeation experiment, and the volume of the supply cell and the receiving cell is 5 mL. Before the experiment, the rat skin is naturally frozen at room temperature, and the skin is fixed between the two chambers, wherein the stratum corneum faces one side of the supply cell and the dermis faces the receiving cell. Then, a blank receiving solution is added to the receiving cell and incubated for 30 minutes at 32±0.5°C and 600rpm. Afterwards, a 40% PEG400-water saturated solution of left thyroxine sodium is added to part of the supply cell as a control group, and a 40% PEG400-water saturated solution of left thyroxine sodium containing isopropyl myristate, azone, oleic acid, propylene glycol, and polyglycerol fatty acid ester as a permeation enhancer is added to other supply cells as an experimental group, and the timing is started and the in vitro transdermal permeation behavior of left thyroxine sodium is investigated. 200 μL of solution was taken out from the receiving pool at 1, 3, 6, 9, 12, 24, 48 and 72 h, and an equal volume of isothermal blank receiving solution was added at the same time.
[0019] The present invention optimizes the patch prescription by in vitro release experiment and improves the in vitro release rate of the drug. Determination method: a vertical diffusion cell is used for in vitro drug release experiment, and the receiving cell volume is 10mL. The patch backing layer is attached to a transparent tape as a support and then assembled to the diffusion cell. The temperature is set to 32°C, and a magnetic rod with a stirring speed of 600rpm provides stirring. The sampling time points are 1h, 3h, 6h, 9h, 12h, 24h, and 27h to extract 200μL samples and supplement with an equal volume of equal temperature blank receiving solution (40% PEG400-aqueous solution).
[0020] By using the above methods, the present invention has achieved good technical effects. By using DURO-TAK 87-2852 pressure-sensitive adhesive, the cumulative permeation amount of levothyroxine sodium through the hairless rat skin for 72 hours can exceed 22.976 μg / cm 2 , levothyroxine sodium is stable in the patch.
[0021] The present invention adopts a synergistic penetration-enhancing means, and the cumulative penetration amount in 72 hours is increased by 5.048 times compared with that without a penetration enhancer. The present invention provides a levothyroxine sodium skeleton transdermal patch, which has the advantages of enabling the levothyroxine sodium in the patch to achieve a long-term (2-4 days) continuous administration characteristic with an appropriate transdermal penetration rate, being able to maintain an effective blood drug concentration over a relatively extended period of time, reducing the number of administrations, avoiding the influence of other food drugs on the absorption of levothyroxine sodium, and significantly improving the patient's medication compliance.
[0022] An acrylic pressure-sensitive adhesive matrix suitable for the levothyroxine sodium transdermal delivery system was screened and optimized. The matrix should have the following characteristics: the solubility of levothyroxine sodium in the matrix is greater than 9%wt, and can carry the levothyroxine sodium dose required for effective transdermal treatment for 2-4 days; the levothyroxine sodium can exist stably in the matrix for a long time; the levothyroxine sodium can be continuously released from the matrix at an appropriate rate, with a transdermal rate to maintain an effective therapeutic dose for 2-4 days.
[0023] It adopts a single-layer skeleton-type transdermal patch structure, with a simple preparation process, easy quality control and relatively low cost. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 Release of levothyroxine sodium in response to different penetration enhancers.
[0025] Figure 2 Release of levothyroxine sodium as a function of oleic acid content.
[0026] Figure 3 Permeation of levothyroxine sodium with different permeation enhancers.
[0027] Figure 4Permeation of levothyroxine sodium as a function of different azone contents.
[0028] Figure 5 Permeation of levothyroxine sodium as a function of oleic acid content.
[0029] Figure 6 Permeation of levothyroxine sodium with combined effects of penetration enhancers.
[0030] Figure 7 Schematic diagram of the patch structure. DETAILED DESCRIPTION
[0031] Example 1
[0032] Prepare the levothyroxine sodium transdermal patch according to the following prescription. Accurately weigh the finely ground levothyroxine sodium and dissolve it in a small amount of ethyl acetate, add it to the polyacrylate pressure-sensitive adhesive solution, and then add the penetration enhancer. Stir for 2 hours at room temperature to make it evenly mixed, let it stand for 1 hour to remove bubbles, apply the drug-containing adhesive solution on the backing layer by transfer coating, dry it at 60-70℃ for 10 minutes to remove the process solvent, press the protective layer, punch and cut it into patches of appropriate area, wrap it with aluminum foil, store it at room temperature, and use it within one week. Conduct in vitro release experiments.
[0033]
[0034]
[0035] Example 2
[0036] Pramipexole transdermal patches were prepared using pressure-sensitive adhesives containing different groups. The patches were placed in a high temperature, high humidity, and high light environment. The crystallization of the drug was observed under a microscope to investigate the stability of pramipexole in the pressure-sensitive adhesive.
[0037]
[0038] Example 3
[0039] Levothyroxine sodium transdermal patches were prepared using pressure-sensitive adhesives containing different groups. The patches were placed in an accelerated test chamber (40°C, 75% RH), and the crystallization of the drug was observed under a microscope to investigate the solubility of levothyroxine sodium in the pressure-sensitive adhesive.
[0040]
[0041]
[0042] Based on the results of Examples 1 to 3, it can be found that:
[0043] 1. In the in vitro drug release experiment, the release rate is low because a diffusion cell is used, but the pressure-sensitive adhesive matrix DURO-TAK 2852 has a relatively good release effect.
[0044] 2. The experimental results of influencing factors show that high light conditions have less effect on the patch, while high temperature has a greater effect on the patch. Through microscopic observation under the three factors, only DURO-TAK 2852 did not show crystallization, while other pressure-sensitive adhesive patches showed varying degrees of crystallization within 10 days.
[0045] 3. Through the stability experiment, it was observed that a small amount of crystallization appeared on the fifth day for DURO-TAK 2510, DURO-TAK 4098, DURO-TAK 2051, and DURO-TAK 2052 pressure-sensitive adhesives, and more crystallization appeared on the tenth day. Therefore, their drug loadings were all less than 3%. No crystallization appeared for DURO-TAK 2287 and DURO-TAK 2852, so DURO-TAK 2287 and DURO-TAK 2852 met the stability requirements.
[0046] In summary, since levothyroxine sodium is stable in the DURO-TAK 2852 matrix and has a good release effect, DURO-TAK 2852 was selected as the pressure-sensitive adhesive matrix of the patch.
[0047] Example 4
[0048] According to the specific implementation method and the following prescription, a levothyroxine sodium transdermal patch was prepared, and then an in vitro release experiment and an in vitro permeation experiment were conducted. The results are shown in the following table.
[0049]
[0050] From the results of Example 4, it can be seen that as the drug loading increases, the drug release and penetration effects are better. A higher drug loading is preferred.
[0051] Example 5
[0052] Levothyroxine sodium transdermal patches containing different drug loadings were prepared and placed in an accelerated test chamber (40°C, 75% RH). The drug crystallization was observed under a microscope to investigate the drug loading of levothyroxine sodium in the pressure-sensitive adhesive.
[0053]
[0054] In Example 5, only 12% of the drug loading showed crystallization in 30 days, so the solubility of the drug in DURO-TAK 2852 was between 9% and 12%. The drug loading should not be greater than 9%.
[0055] The drug loading was screened by Examples 4 and 5. The release and penetration of the drug in the patch increased with the increase of the drug loading. Considering the crystallization problem, 9%wt was selected as the drug loading, which can not only ensure that the drug will not crystallize in the pressure-sensitive adhesive, but also ensure the best penetration effect. Example 6 According to the specific implementation method and the following prescription, a levothyroxine sodium transdermal patch was prepared, and then an in vitro release experiment was carried out. The release curve obtained is shown in the attached figure. Figure 1-2 shown.
[0056] Patch number Pressure sensitive adhesive type Drug loading Types of penetration enhancers Penetration enhancer content 1-1 DURO-TAK 87-2852 3% OA 5% 1-2 DURO-TAK 87-2852 3% PG 5% 1-3 DURO-TAK 87-2852 3% NZ 5% 1-4 DURO-TAK 87-2852 3% POCC 5% 1-5 DURO-TAK 87-2852 3% IPM 5% 1-6 DURO-TAK 87-2852 3% None 0 2-1 DURO-TAK 87-2852 3% OA 3% 2-2 DURO-TAK 87-2852 3% OA 6% 2-3 DURO-TAK 87-2852 3% OA 9% 2-4 DURO-TAK 87-2852 3% OA 12%
[0057] Example 7
[0058] A saturated solution of 40%-PEG400 of levothyroxine sodium was prepared, and the same proportion and type of penetration enhancer as in Example 6 were added, and then an in vitro permeation experiment was performed. The permeation curve obtained is shown in the attached figure. Figure 3 shown.
[0059] Example 8
[0060] The levothyroxine sodium transdermal patch was prepared according to the following prescription, and then an in vitro permeation experiment was performed. The permeation curve obtained is shown in the attached figure. Figure 4-6 shown.
[0061] Patch number Pressure sensitive adhesive type Drug loading Types of penetration enhancers Penetration enhancer content 3-1 DURO-TAK 87-2852 9% NZ 1% 3-2 DURO-TAK 87-2852 9% NZ 2% 3-3 DURO-TAK 87-2852 9% NZ 3% 3-4 DURO-TAK 87-2852 9% None 0 4-1 DURO-TAK 87-2852 9% OA 3% 4-2 DURO-TAK 87-2852 9% OA 6% 4-3 DURO-TAK 87-2852 9% OA 9% 4-4 DURO-TAK 87-2852 9% OA 12% 5-1 DURO-TAK 87-2852 9% OA+NZ 9%+1%
[0062] Comprehensive analysis of Examples 6 to 8 can lead to the following conclusions:
[0063] 1. The release effects of five chemical permeation enhancers with different permeation mechanisms on L-T4 in the patch were evaluated. The results of the release enhancement of levothyroxine sodium in the pressure-sensitive adhesive matrix by OA, PG, NZ, POCC, and IPM with equal mass fractions (5%) were compared. Figure 1 As shown, compared with the blank group (1-6), the five penetration enhancers can enhance the release effect, among which oleic acid has a stronger promoting effect on L-T4-PSA, OA can increase the release amount of L-T4 in the matrix by 1.646 times, and PG, NZ, POCC, and IPM can only increase the content of L-T4 by 0.960, 1.214, 1.276, and 1.15 times, respectively.
[0064] 2. Usually, the penetration enhancement study on drug saturated solution can better show the penetration enhancement effect and eliminate the interference of patch matrix. The penetration enhancement effects of five chemical penetration enhancers with different penetration enhancement mechanisms on L-T4 saturated solution are as follows Figure 3 Compared with the blank group (1-6), NZ can significantly increase the cumulative permeation of L-T4 by 5.137 times, and the permeation of L-T4 in the OA, PG, POCC, and IPM groups increased by 1.467, 1.98, 2.615, and 0.972 times, respectively.
[0065] 3. Overall, although oleic acid has a strong effect in promoting release, its penetration-promoting effect is not good; and although azone has an excellent penetration-promoting effect, it cannot improve the release of drugs in the matrix. For the two complementary processes of release and penetration, the combined use of these two compounds may greatly promote the skin penetration of drugs. Therefore, we used azone and oleic acid together and conducted prescription screening. The results are as follows Figure 2 , 4 , 5. As the OA content increases, the drug release effect is better ( Figure 2 ). It seems to reach a certain plateau when it reaches 9%, and the release effect does not increase much when it increases to 12%. As the OA content increases, its penetration effect shows a trend consistent with the release effect ( Figure 5 ). As the NZ content increases, the penetration effect of the L-T4 patch decreases ( Figure 4 ). Azone has a certain ability to promote drug dissolution. This may be due to the increase in the content of NZ, which leads to an increase in the solubility of L-T4 in the patch matrix, which is not conducive to its release from the patch. Considering the effect and skin irritation, 9% wt OA and 1% wt azone were finally selected for the preparation of the patch.
[0066] 4. Drug penetration results such as Figure 6 As shown in Figure 2, the cumulative permeability of the OA+NZ group was 22.976±3.312μg / cm at 72h. 2 , OA group: 8.858±0.877μg / cm 2 , NZ group: 16.107±2.076μg / cm 2 Compared with NZ alone, oleic acid alone and the blank group, the combination of OA and NZ can significantly improve the penetration of L-T4 in the patch.
Claims
1. A long-acting transdermal patch of levothyroxine sodium, comprising layers arranged in the following order: a backing layer, a drug-containing pressure-sensitive adhesive layer, and an anti-adhesive layer; Features: The backing layer and the anti-adhesive layer are both PET films; The pressure-sensitive adhesive in the drug-containing pressure-sensitive adhesive layer is an acrylic pressure-sensitive adhesive; the acrylic pressure-sensitive adhesive in the drug-containing pressure-sensitive adhesive layer is 73%-97% by weight; the levothyroxine sodium is 3%-12% by weight; and the penetration enhancer is 1%-15% by weight.
2. A long-acting transdermal patch of levothyroxine sodium according to claim 1, Features: The acrylic pressure-sensitive adhesive is selected from one of DURO-TAK 87-2287, DURO-TAK 87-2510, DURO-TAK 87-2852, DURO-TAK 87-4098, DURO-TAK 87-2051 and DURO-TAK 87-2052.
3. A long-acting transdermal patch of levothyroxine sodium according to claim 1, Features: The penetration enhancer is selected from one or more of isopropyl myristate, azone, oleic acid, propylene glycol, and polyglycerol fatty acid ester.
4. A long-acting transdermal patch of levothyroxine sodium according to any one of claims 1 to 3, Features: The levothyroxine sodium transdermal patch can maintain an effective transdermal therapeutic dose for 2-4 days; the thickness of the patch is 100 to 200 microns.
5. The long-acting transdermal patch of levothyroxine sodium according to claim 1, Features: The skeleton-type patch was prepared by solvent method.
Citation Information
Patent Citations
Oxygen-impervious packaging and method for storing thyroid hormone
CN101106981A
Transdermal patch containing pramipexole
CN103432104A
Transdermal patch containing formoterol or fumarate thereof
CN105147642A
JP2021.121011
